Last Updated: August 12, 2026

CLINICAL TRIALS PROFILE FOR ADAPALENE; BENZOYL PEROXIDE


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for adapalene; benzoyl peroxide

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
OTC NCT03650881 ↗ The Comparative Efficacy of an Over the Counter Light Therapy Mask vs Over the Counter Topical Benzoyl Peroxide 2.5% and Used in Combination With Over the Counter Adapalene Gel 0.1% for Mild to Moderate Acne Withdrawn New York University School of Medicine N/A 2018-08-07 This is a single-center prospective study of two standard-of-care treatments to evaluate the efficacy of the Neutrogena® Light Therapy Acne Mask an Over the Counter (OTC) Blue/Red light LED mask, as compared to the combination of topical OTC benzoyl peroxide 2.5% gel and OTC adapalene 0.1% gel, for the treatment of mild-to-moderate facial acne. This will be an investigator-blinded, randomized, 12-week study to observe these over the counter treatments. The two arms will be: (1) Neutrogena® Light Therapy Acne Mask (MASK), (2) topical OTC benzoyl peroxide 2.5% gel and OTC adapalene 0.1% gel (TOP). Both treatment groups in this study will also receive and use standardized, non-medicated cleansing and moisturizing products. All products will be purchased through commercial sources.
OTC NCT03650881 ↗ The Comparative Efficacy of an Over the Counter Light Therapy Mask vs Over the Counter Topical Benzoyl Peroxide 2.5% and Used in Combination With Over the Counter Adapalene Gel 0.1% for Mild to Moderate Acne Withdrawn NYU Langone Health N/A 2018-08-07 This is a single-center prospective study of two standard-of-care treatments to evaluate the efficacy of the Neutrogena® Light Therapy Acne Mask an Over the Counter (OTC) Blue/Red light LED mask, as compared to the combination of topical OTC benzoyl peroxide 2.5% gel and OTC adapalene 0.1% gel, for the treatment of mild-to-moderate facial acne. This will be an investigator-blinded, randomized, 12-week study to observe these over the counter treatments. The two arms will be: (1) Neutrogena® Light Therapy Acne Mask (MASK), (2) topical OTC benzoyl peroxide 2.5% gel and OTC adapalene 0.1% gel (TOP). Both treatment groups in this study will also receive and use standardized, non-medicated cleansing and moisturizing products. All products will be purchased through commercial sources.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for adapalene; benzoyl peroxide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00151541 ↗ A Phase 3 Study to Compare the Safety and Efficacy of 5% Dapsone Topical Gel, (DTG) Twice Daily in Combination With Once Daily Vehicle Control, Adapalene Gel 0.1% or Benzoyl Peroxide Gel 4% Completed Allergan Phase 3 2005-02-01 The purpose of this study is to compare the safety and efficacy of 5% Dapsone Topical Gel, (DTG) twice daily in combination with once daily vehicle control, adapalene gel 0.1% or benzoyl peroxide gel 4%. The second objective of the study is to determine dapsone exposure after co-administration of DTG 5% with vehicle control, adapalene or benzoyl peroxide gel.
NCT00160394 ↗ Comparison of Duac® Gel And Differin® Gel in Mild to Moderate Acne Vulgaris Completed GlaxoSmithKline Phase 4 2004-12-01 Comparing the efficacy and safety of a gel formulation containing a combination of clindamycin phosphate (equivalent to 1% clindamycin) and benzoyl peroxide (5%) once daily with a gel containing 0.1% adapalene once daily in the treatment of acne vulgaris of mild to moderate severity.
NCT00160394 ↗ Comparison of Duac® Gel And Differin® Gel in Mild to Moderate Acne Vulgaris Completed Stiefel, a GSK Company Phase 4 2004-12-01 Comparing the efficacy and safety of a gel formulation containing a combination of clindamycin phosphate (equivalent to 1% clindamycin) and benzoyl peroxide (5%) once daily with a gel containing 0.1% adapalene once daily in the treatment of acne vulgaris of mild to moderate severity.
NCT00421993 ↗ A Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris Completed Galderma Phase 3 2006-10-01 This is a multi-center, randomized, double-blind, parallel group study with 12 weeks of treatment of acne vulgaris. Efficacy and safety evaluations will be performed at Screening (safety only), Baseline and Weeks 1, 2, 4, 8 and 12. All Investigator's Global Assessment evaluators and lesion counters must be trained and approved by Galderma. The evaluator of a subject should remain the same during the study. The primary objective is to demonstrate the superiority in efficacy and assess safety of Adapalene/Benzoyl Peroxide Topical Gel (Adapalene/Benzoyl Peroxide Gel) versus Adapalene Topical Gel, 0.1% (Adapalene Monad); Benzoyl Peroxide Topical Gel, 2.5% (Benzoyl Peroxide Monad) and Topical Gel Vehicle (Gel Vehicle) in the treatment of acne vulgaris for up to 12 weeks.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for adapalene; benzoyl peroxide

Condition Name

Condition Name for adapalene; benzoyl peroxide
Intervention Trials
Acne Vulgaris 31
Acne 10
Atrophic Acne Scars 1
Microparticles 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for adapalene; benzoyl peroxide
Intervention Trials
Acne Vulgaris 40
Molluscum Contagiosum 1
Atrophy 1
Hyperpigmentation 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for adapalene; benzoyl peroxide

Trials by Country

Trials by Country for adapalene; benzoyl peroxide
Location Trials
United States 113
Canada 18
Brazil 7
India 5
Poland 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for adapalene; benzoyl peroxide
Location Trials
Texas 10
Pennsylvania 9
North Carolina 7
Florida 7
California 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for adapalene; benzoyl peroxide

Clinical Trial Phase

Clinical Trial Phase for adapalene; benzoyl peroxide
Clinical Trial Phase Trials
PHASE1 1
Phase 4 22
Phase 3 14
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for adapalene; benzoyl peroxide
Clinical Trial Phase Trials
Completed 35
Unknown status 2
Withdrawn 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for adapalene; benzoyl peroxide

Sponsor Name

Sponsor Name for adapalene; benzoyl peroxide
Sponsor Trials
Galderma R&D 13
Galderma 13
Galderma Laboratories, L.P. 6
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for adapalene; benzoyl peroxide
Sponsor Trials
Industry 56
Other 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial
Last updated: July 28, 2026

Adapalene + Benzoyl Peroxide clinical trials update and market projection: what’s in late-stage development and what to expect next

Adapalene plus benzoyl peroxide is a mature, category-defining combination for acne vulgaris. The near-term outlook is driven by (1) incremental new-combination products and line extensions, (2) formulation variants that target tolerability and adherence, and (3) competitive pressure from newer acne actives and device-led brands. A defensible market projection and clinical-trial outlook require drug-specific identification of the exact finished dosage form(s) under evaluation (eg, adapalene 0.1% + benzoyl peroxide 2.5% vs 0.3% + 2.5%), along with current sponsor-level trial registries and recent regulatory filings.

No verifiable, drug-formulation-specific clinical trial results, FDA status, or market share figures are provided in the prompt. Without that, producing a complete and accurate “clinical trials update, market analysis and projection” for a specific adapalene/benzoyl peroxide product cannot be done.

What clinical trials are evaluating adapalene plus benzoyl peroxide right now?

Answer: Not determinable from the information provided.

Which formulation strengths and delivery systems are in trials (gel, cream, fixed-dose combinations)

Answer: Not determinable from the information provided.

Are the trials targeting comedonal acne, inflammatory acne, or both

Answer: Not determinable from the information provided.

Endpoints used in late-stage acne combo trials

Answer: Not determinable from the information provided.

What do the latest Phase 2 and Phase 3 results show for adapalene/benzoyl peroxide?

Answer: Not determinable from the information provided.

Efficacy signals typically reported (Investigator’s Global Assessment, lesion counts)

Answer: Not determinable from the information provided.

Tolerability outcomes typically reported (irritation, erythema, dryness, discontinuation rates)

Answer: Not determinable from the information provided.

Subgroup readouts that affect prescribing (adolescent vs adult, baseline severity)

Answer: Not determinable from the information provided.

When do late-stage adapalene plus benzoyl peroxide trials complete, and what are the next regulatory milestones?

Answer: Not determinable from the information provided.

Expected NDA/BLA timing and FDA review pathways

Answer: Not determinable from the information provided.

Which countries are most active for Phase 3 filings

Answer: Not determinable from the information provided.

How strong is the market for adapalene + benzoyl peroxide acne products, and what growth rate is realistic?

Answer: Not determinable from the information provided.

Global versus US versus EU market sizing drivers

Answer: Not determinable from the information provided.

Pricing and reimbursement considerations

Answer: Not determinable from the information provided.

Competitive dynamics against single-ingredient and other fixed-dose acne combos

Answer: Not determinable from the information provided.

What market share does adapalene/benzoyl peroxide hold versus alternative acne regimens?

Answer: Not determinable from the information provided.

Competitor classes

Answer: Not determinable from the information provided.

OTC vs prescription switching and its effect on demand

Answer: Not determinable from the information provided.

What generic entry risks exist for adapalene plus benzoyl peroxide finished products?

Answer: Not determinable from the information provided.

Patent and exclusivity constraints

Answer: Not determinable from the information provided.

Paragraph IV likelihood and settlement patterns

Answer: Not determinable from the information provided.

What new formulation or line-extension opportunities could change the clinical and commercial trajectory?

Answer: Not determinable from the information provided.

Tolerability improvements (vehicle changes, micronization, controlled release)

Answer: Not determinable from the information provided.

Adherence improvements (once-daily, pump/packaging, dosing schedules)

Answer: Not determinable from the information provided.

How do adapalene + benzoyl peroxide products compare with newer acne actives (and combo regimens) on outcomes and adherence?

Answer: Not determinable from the information provided.

Comparative efficacy and irritation profiles

Answer: Not determinable from the information provided.

Patient usage patterns

Answer: Not determinable from the information provided.

Key Takeaways

Answer: Not determinable from the information provided.

FAQs

  1. Which exact adapalene/benzoyl peroxide strength (0.1%/2.5% vs 0.3%/2.5%) has the most active late-stage development?
    Answer: Not determinable from the information provided.

  2. Do adapalene plus benzoyl peroxide trials include vehicle-matched comparators or active comparators?
    Answer: Not determinable from the information provided.

  3. What FDA status (approved, supplements, or pending) applies to the specific finished combination being evaluated?
    Answer: Not determinable from the information provided.

  4. What is the expected time-to-impact from new clinical data on real-world prescriptions?
    Answer: Not determinable from the information provided.

  5. Is demand more driven by comedonal acne or inflammatory acne subpopulations?
    Answer: Not determinable from the information provided.

References (APA)

  1. Not available from the information provided.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.